1. A New Way Out of the Predicament of Anaplastic Thyroid Carcinoma From Existing Data Analysis
   Yikun Zhou et al, 2022, Frontiers in Endocrinology CrossRef
2. New Insights into Immune Cells and Immunotherapy for Thyroid Cancer
   Yujia Tao et al, 2023, Immunological Investigations CrossRef
3. Poorly differentiated thyroid carcinoma: molecular, clinico-pathological hallmarks and therapeutic perspectives
   Valentina CIRELLO et al, 2024, Panminerva Medica CrossRef
4. TERT promoter mutations in thyroid cancer
   Michiko Matsuse et al, 2023, Endocrine Journal CrossRef
5. Aggressive variants of follicular cell-derived thyroid carcinoma: an overview
   Cristina Pizzimenti et al, 2022, Endocrine CrossRef
6. Anaplastic Thyroid Carcinoma: An Update
   Arnaud Jannin et al, 2022, Cancers CrossRef
7. Update on Fundamental Mechanisms of Thyroid Cancer
   Alessandro Prete et al, 2020, Frontiers in Endocrinology CrossRef
8. The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy
   Antonio Matrone et al, 2019, Frontiers in Oncology CrossRef
9. Correlation of ThyroSeq Results with Surgical Histopathology in Cytologically Indeterminate Thyroid Nodules
   Patrick D. Chin et al, 2020, Endocrine Pathology CrossRef
10. Evaluation of E-Cadherin and β-Catenin Immunoreactivity for Determining Undifferentiated Cells in Anaplastic Thyroid Carcinoma
    Risa Kanematsu et al, 2021, Pathobiology CrossRef
11. Deep response to a combination of mTOR inhibitor temsirolimus and dual immunotherapy of nivolumab/ipilimumab in poorly differentiated thyroid carcinoma with PTEN mutation: a case report and literature review
    Youjin Oh et al, 2024, Frontiers in Endocrinology CrossRef
12. Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer
    Tanner Fullmer et al, 2021, Frontiers in Endocrinology CrossRef
13. Pre- and Post-operative Circulating Tumoral DNA in Patients With Medullary Thyroid Carcinoma
    Raffaele Ciampi et al, 2022, The Journal of Clinical Endocrinology & Metabolism CrossRef